Delivering moments that matter
We envision a future where we move from symptomatic treatments to disease modification and, eventually, a cure for severe diseases. U.S. R&D is part of our global work in disease areas where we have deep expertise:
UCB is on a mission to cure epilepsy, approaching a 30-year history of providing real, impactful, and life-improving solutions to patients. Our diverse pipeline of treatment approaches and patient support includes pursing multiple MOAs to address the disease’s conditions with different research modalities
Our extensive research of immune-mediated inflammatory diseases explores new populations with unmet need and novel solutions for hard-to-treat conditions. To change the future of immunology care withing the next decade, we’re also using trailblazing research approaches to move from symptomatic treatment to disease modification and, eventually, cures.
When it comes to rare disease treatments, one size does not fit all. We focus on solving the challenge of lived experiences for individual patients living with rare neurological immunological diseases and developing tailored solutions for people where current options offer little hope.